PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis

Frontiers in Immunology

Volumn 9, Issue , 2018, Pages

  Day, Cheryl L ^a,b   Abrahams, Deborah A ^c   Bunjun, Rubina ^d   Stone, Lynnett ^c   de Kock, Marwou ^c   Walzl, Gerhard ^e   Wilkinson, Robert J ^d,f,g   Burgers, Wendy A ^d   Hanekom, Willem A ^c,h  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF STELLENBOSCH   (South Africa)

^f THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

CD4 T cell; CD8 T cell; IFN ; PD 1; proliferation; tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADOLESCENT; ADULT; AGED; BACTERIAL LOAD; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; FEMALE; HUMAN; IMMUNOLOGY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TH1 CELL; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, BACTERIAL; BACTERIAL LOAD; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TH1 CELLS; TUBERCULOSIS, PULMONARY; UP-REGULATION; YOUNG ADULT;

EID: 85058921630     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.01995     Document Type: Article

References (80)

1. WHO Publication. Global Tuberculosis Report 2017 (2017). Available Online at: http://www.who.int/tb/publications/global_report/en/
2. Houben RM Dodd PJ. The Global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. (2016) 13:e1002152. 10.1371/journal.pmed.100215227780211
3. Barry CE 3rd Boshoff HI Dartois V Dick T Ehrt S Flynn J et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. (2009) 7:845–55. 10.1038/nrmicro223619855401
4. Caruso AM Serbina N Klein E Triebold K Bloom BR Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol. (1999) 162:5407–16. 10228018
5. Mogues T Goodrich ME Ryan L LaCourse R North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med. (2001) 193:271–80. 10.1084/jem.193.3.27111157048
6. Serbina NV Lazarevic V Flynn JL. CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol. (2001) 167:6991–7000. 10.4049/jimmunol.167.12.699111739519
7. Lin PL Rutledge T Green AM Bigbee M Fuhrman C Klein E et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in Cynomolgus macaques. AIDS Res Hum Retroviruses (2012) 28:1693–702. 10.1089/aid.2012.002822480184
8. Yao S Huang D Chen CY Halliday L Wang RC Chen ZW. CD4+ T cells contain early extrapulmonary tuberculosis (TB) dissemination and rapid TB progression and sustain multieffector functions of CD8+ T and CD3- lymphocytes: mechanisms of CD4+ T cell immunity. J Immunol. (2014) 192:2120–32. 10.4049/jimmunol.130137324489088
9. Antonucci G Girardi E Raviglione MC Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA (1995) 274:143–8. 10.1001/jama.1995.035300200610337596002
10. Lawn SD Zumla AI. Tuberculosis. Lancet (2011) 378:57–72. 10.1016/S0140-6736(10)62173-321420161
11. Selwyn PA Hartel D Lewis VA Schoenbaum EE Vermund SH Klein RS et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. (1989) 320:545–50. 10.1056/NEJM1989030232009012915665
12. Bruns H Meinken C Schauenberg P Harter G Kern P Modlin RL et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest. (2009) 119:1167–77. 10.1172/JCI3848219381021
13. Stegelmann F Bastian M Swoboda K Bhat R Kiessler V Krensky AM et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol. (2005) 175:7474–83. 10.4049/jimmunol.175.11.747416301655
14. Stenger S Hanson DA Teitelbaum R Dewan P Niazi KR Froelich CJ et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science (1998) 282:121–5. 10.1126/science.282.5386.1219756476
15. Chen CY Huang D Wang RC Shen L Zeng G Yao S et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. (2009) 5:e1000392. 10.1371/journal.ppat.100039219381260
16. Flynn JL Goldstein MM Triebold KJ Koller B Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA. (1992) 89:12013–7. 10.1073/pnas.89.24.120131465432
17. Sousa AO Mazzaccaro RJ Russell RG Lee FK Turner OC Hong S et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc Natl Acad Sci USA. (2000) 97:4204–8. 10.1073/pnas.97.8.420410760288
18. van Pinxteren LA Cassidy JP Smedegaard BH Agger EM Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol. (2000) 30:3689–98. 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
19. Lalvani A Brookes R Wilkinson RJ Malin AS Pathan AA Andersen P et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci USA. (1998) 95:270–5. 10.1073/pnas.95.1.2709419365
20. Day CL Abrahams DA Lerumo L Janse van Rensburg E Stone L O'Rie T et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. (2011) 187:2222–32. 10.4049/jimmunol.110112221775682
21. Millington KA Innes JA Hackforth S Hinks TS Deeks JJ Dosanjh DP et al. Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. (2007) 178:5217–26. 10.4049/jimmunol.178.8.521717404305
22. Sutherland JS Adetifa IM Hill PC Adegbola RA Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol. (2009) 39:723–9. 10.1002/eji.20083869319224636
23. Harari A Rozot V Enders FB Perreau M Stalder JM Nicod LP et al. Dominant TNF-alpha(+) Mycobacterium tuberculosis-specific CD4(+) T cell responses discriminate between latent infection and active disease. Nat Med. (2011) 17:372–6. 10.1038/nm.229921336285
24. Day CL Moshi ND Abrahams DA van Rooyen M O'Rie T de Kock M et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8 T cells with a pro-apoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS ONE (2014) 9:e94949. 10.1371/journal.pone.0094949
25. Smith SM Klein MR Malin AS Sillah J Huygen K Andersen P et al. Human CD8(+) T cells specific for Mycobacterium tuberculosis secreted antigens in tuberculosis patients and healthy BCG-vaccinated controls in The Gambia. Infect Immun. (2000) 68:7144–8. 10.1128/IAI.68.12.7144-7148.200011083843
26. Andersson J Samarina A Fink J Rahman S Grundstrom S. Impaired expression of perforin and granulysin in CD8+ T cells at the site of infection in human chronic pulmonary tuberculosis. Infect Immun. (2007) 75:5210–22. 10.1128/IAI.00624-0717664265
27. Wherry EJ. T cell exhaustion. Nat Immunol. (2011) 12:492–9. 10.1038/ni.203521739672
28. Wherry EJ Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. (2015) 15:486–99. 10.1038/nri386226205583
29. Wykes MN Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol. (2018) 18:91–104. 10.1038/nri.2017.11228990586
30. Ribas A Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (2018) 359:1350–5. 10.1126/science.aar406029567705
31. Behr MA Warren SA Salamon H Hopewell PC Ponce de Leon A Daley CL et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet (1999) 353:444–9. 10.1016/S0140-6736(98)03406-09989714
32. Hobby GL Holman AP Iseman MD Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. (1973) 4:94–104. 10.1128/AAC.4.2.944208508
33. Qiu L Huang D Chen CY Wang R Shen L Shen Y et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis. (2008) 198:1514–9. 10.1086/59244818811584
34. Barber DL Mayer-Barber KD Feng CG Sharpe AH Sher A. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. J Immunol. (2011) 186:1598–607. 10.4049/jimmunol.100330421172867
35. Lazar-Molnar E Chen B Sweeney KA Wang EJ Liu W Lin J et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci USA. (2010) 107:13402–7. 10.1073/pnas.100739410720624978
36. Tousif S Singh Y Prasad DV Sharma P Van Kaer L Das G. T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS ONE. (2011) 6:e19864. 10.1371/journal.pone.001986421589883
37. Sakai S Kauffman KD Sallin MA Sharpe AH Young HA Ganusov VV et al. CD4 T Cell-Derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. (2016) 12:e1005667. 10.1371/journal.ppat.100566727244558
38. Alvarez IB Pasquinelli V Jurado JO Abbate E Musella RM de la Barrera SS et al. Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis. J Infect Dis. (2010) 202:524–32. 10.1086/65493220617899
39. McNab FW Berry MP Graham CM Bloch SA Oni T Wilkinson KA et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol. (2011) 41:1941–7. 10.1002/eji.20114142121509782
40. Shen L Gao Y Liu Y Zhang B Liu Q Wu J et al. PD-1/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci Rep. (2016) 6:38362. 10.1038/srep3836227924827
41. Singh A Mohan A Dey AB Mitra DK. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. (2013) 208:603–15. 10.1093/infdis/jit20623661793
42. Adekambi T Ibegbu CC Kalokhe AS Yu T Ray SM Rengarajan J. Distinct effector memory CD4(+) T Cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS ONE (2012) 7:e36046. 10.1371/journal.pone.003604622545156
43. Kern F Bunde T Faulhaber N Kiecker F Khatamzas E Rudawski IM et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis. (2002) 185:1709–16. 10.1086/34063712085315
44. Kern F Faulhaber N Frommel C Khatamzas E Prosch S Schonemann C et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. (2000) 30:1676–82. 10.1002/1521-4141(200006)30:6<1676::AID-IMMU1676>3.0.CO;2-V10898504
45. Maecker HT Dunn HS Suni MA Khatamzas E Pitcher CJ Bunde T et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods (2001) 255:27–40. 10.1016/S0022-1759(01)00416-111470284
46. Kalsdorf B Scriba TJ Wood K Day CL Dheda K Dawson R et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med. (2009) 180:1262–70. 10.1164/rccm.200907-1011OC19797156
47. Kannanganat S Ibegbu C Chennareddi L Robinson HL Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol. (2007) 81:8468–76. 10.1128/JVI.00228-0717553885
48. Kannanganat S Kapogiannis BG Ibegbu C Chennareddi L Goepfert P Robinson HL et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol. (2007) 81:12071–6. 10.1128/JVI.01261-07
49. Darrah PA Patel DT De Luca PM Lindsay RW Davey DF Flynn BJ et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. (2007) 13:843–50. 10.1038/nm159217558415
50. Barber DL Wherry EJ Masopust D Zhu B Allison JP Sharpe AH et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439:682–7. 10.1038/nature0444416382236
51. Day CL Kaufmann DE Kiepiela P Brown JA Moodley ES Reddy S et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 443:350–4. 10.1038/nature0511516921384
52. Rozot V Patrizia A Vigano S Mazza-Stalder J Idrizi E Day CL et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis. (2015) 60:432–7. 10.1093/cid/ciu79525362202
53. Rozot V Vigano S Mazza-Stalder J Idrizi E Day CL Perreau M et al. Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol. (2013) 43:1568–77. 10.1002/eji.20124326223456989
54. Velu V Titanji K Zhu B Husain S Pladevega A Lai L et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2009) 458:206–10. 10.1038/nature0766219078956
55. Fuller MJ Callendret B Zhu B Freeman GJ Hasselschwert DL Satterfield W et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA. (2013) 110:15001–6. 10.1073/pnas.131277211023980172
56. Porichis F Kwon DS Zupkosky J Tighe DP McMullen A Brockman MA et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood (2011) 118:965–74. 10.1182/blood-2010-12-32807021652684
57. Porichis F Hart MG Zupkosky J Barblu L Kwon DS McMullen A et al. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol. (2014) 88:2508–18. 10.1128/JVI.02034-1324352453
58. Trautmann L Janbazian L Chomont N Said EA Gimmig S Bessette B et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. (2006) 12:1198–202. 10.1038/nm148216917489
59. Zhang Z Zhang JY Wherry EJ Jin B Xu B Zou ZS et al. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology (2008) 134:1938–49, 49 e1–3. 10.1053/j.gastro.2008.03.03718455515
60. Golden-Mason L Palmer B Klarquist J Mengshol JA Castelblanco N Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol. (2007) 81:9249–58. 10.1128/JVI.00409-0717567698
61. Urbani S Amadei B Tola D Massari M Schivazappa S Missale G et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. (2006) 80:11398–403. 10.1128/JVI.01177-0616956940
62. Urbani S Amadei B Tola D Pedrazzi G Sacchelli L Cavallo MC et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol. (2008) 48:548–58. 10.1016/j.jhep.2007.12.01418280607
63. Saharia KK Petrovas C Ferrando-Martinez S Leal M Luque R Ive P et al. Tuberculosis therapy modifies the cytokine profile, maturation state, and expression of inhibitory molecules on Mycobacterium tuberculosis-specific CD4+ T-cells. PLoS ONE (2016) 11:e0158262. 10.1371/journal.pone.015826227367521
64. Yang JD Mott D Sutiwisesak R Lu YJ Raso F Stowell B et al. Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophages. PLoS Pathog. (2018) 14:e1007060. 10.1371/journal.ppat.100706029782535
65. Neff CP Chain JL MaWhinney S Martin AK Linderman DJ Flores SC et al. Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects. Am J Respir Crit Care Med. (2015) 191:464–73. 10.1164/rccm.201408-1521OC25536276
66. Palmer BE Mack DG Martin AK Gillespie M Mroz MM Maier LA et al. Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease. J Immunol. (2008) 180:2704–12. 10.4049/jimmunol.180.4.270418250483
67. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252–64. 10.1038/nrc323922437870
68. Brahmer JR Tykodi SS Chow LQ Hwu WJ Topalian SL Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. (2012) 366:2455–65. 10.1056/NEJMoa120069422658128
69. Hodi FS O'Day SJ McDermott DF Weber RW Sosman JA Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. (2010) 363:711–23. 10.1056/NEJMoa100346620525992
70. Robert C Thomas L Bondarenko I O'Day S Weber J Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. (2011) 364:2517–26. 10.1056/NEJMoa110462121639810
71. Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. (2012) 366:2443–54. 10.1056/NEJMoa120069022658127
72. Petrovas C Casazza JP Brenchley JM Price DA Gostick E Adams WC et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. (2006) 203:2281–92. 10.1084/jem.2006149616954372
73. Jurado JO Alvarez IB Pasquinelli V Martinez GJ Quiroga MF Abbate E et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol. (2008) 181:116–25. 10.4049/jimmunol.181.1.11618566376
74. Fujita K Terashima T Mio T. Anti-PD1 Antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. (2016) 11:2238–40. 10.1016/j.jtho.2016.07.00627423391
75. Jensen KH Persson G Bondgaard AL Pohl M. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. Acta Oncol. (2018) 57:1127–8. 10.1080/0284186X.2018.143387729384034
76. Lee JJ Chan A Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol. (2016) 55:519–20. 10.3109/0284186X.2015.112501726754959
77. Govender L Abel B Hughes EJ Scriba TJ Kagina BM de Kock M et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine (2010) 29:51–7. 10.1016/j.vaccine.2010.10.02220974305
78. Brown KE Freeman GJ Wherry EJ Sharpe AH. Role of PD-1 in regulating acute infections. Curr Opin Immunol. (2010) 22:397–401. 10.1016/j.coi.2010.03.00720427170
79. Paris RM Petrovas C Ferrando-Martinez S Moysi E Boswell KL Archer E et al. Selective loss of early differentiated, highly functional PD1high CD4 T cells with HIV progression. PLoS ONE (2015) 10:e0144767. 10.1371/journal.pone.014476726678998
80. Foldi J Kozhaya L McCarty B Mwamzuka M Marshed F Ilmet T et al. HIV-infected children have elevated levels of PD-1+ memory CD4 T cells with low proliferative capacity and high inflammatory cytokine effector functions. J Infect Dis. (2017) 216:641–50. 10.1093/infdis/jix34128934428